# Mobile App for Improving Adherence of Rivoxaban (RIVOX-AF)

Study · id `cardio:ct-nct05557123` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05557123](<https://clinicaltrials.gov/study/NCT05557123>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05557123

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 637 participants.

## Technical summary

Registry record NCT05557123. Randomized; no masking; primary purpose treatment. Start 2022-03-10 (actual); primary completion 2025-12-16 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 637 participants (enrolled count; ClinicalTrials.gov record NCT05557123, source copy `cardio:ctgov-nct05557123-2026-05-19`, retrieved 2026-10-26)
- Started: 2022-03-10 (actual) (ClinicalTrials.gov record NCT05557123, source copy `cardio:ctgov-nct05557123-2026-05-19`, retrieved 2026-10-26)
- Primary completion: 2025-12-16 (actual) (ClinicalTrials.gov record NCT05557123, source copy `cardio:ctgov-nct05557123-2026-05-19`, retrieved 2026-10-26)
- Completion: 2025-12-16 (actual) (ClinicalTrials.gov record NCT05557123, source copy `cardio:ctgov-nct05557123-2026-05-19`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT05557123, source copy `cardio:ctgov-nct05557123-2026-05-19`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05557123-2026-05-19`, retrieved 2026-10-26)

## The registry's words

- Brief title: Mobile App for Improving Adherence of Rivoxaban (RIVOX-AF)
- Condition: Atrial Fibrillation
- Intervention (Device): MEDI-app
- Lead sponsor: Seoul National University Bundang Hospital
- Lead sponsor class: OTHER
- Collaborator: SAMJIN PHARM
- Collaborator class: UNKNOWN

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry lists this organization as the lead sponsor: Seoul National University Bundang Hospital (`cardio:org-seoul-national-university-bundang-hospital`)

## Provenance

Content hash: 633b059a9b47710cb3f059cf7c7ad9c808d249e4e8a775c4fa01c39165954ead
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
